Adv Ther (2009) 26(7):736.
DOI 10.1007/s12325-009-0051-4

ERRATUM

Saxagliptin: a New DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Abd A. Tahrani · Milan K. Piya · Anthony H. Barnett

In the review by Abd Tahrani and colleagues entitled 'Saxagliptin: a New DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus', published in Advances in Therapy 2009 Mar;26(3):249-262, the section on page 252 that reads:

"Saxagliptin demonstrates greater specificity for DPP-4 than for either the DPP-8 or DPP-9 enzymes (400- and 75-fold, respectively).[46] The active metabolite of saxagliptin (BMS-510849) is two-fold less potent than the parent. Both saxagliptin and its metabolite are highly selective (>4000-fold) for the inhibition of DPP-4 compared with a range of other proteases (selectivity of sitagliptin and vildagliptin for DPP-4 is >2600 and 32-250-fold, respectively, compared with DPP-8/9).[44]"

could be open to misinterpretation, and should have appeared as follows:

"Saxagliptin demonstrates greater selectivity for DPP-4 than for either the DPP-8 or DPP-9 enzymes (400- and 75-fold, respectively).[46] The active metabolite of saxagliptin (BMS-510849) is two-fold less potent than the parent. Selectivity of sitagliptin and vildagliptin for DPP-4 is >2600 and 32-250-fold greater, respectively, compared with DPP-8/9.[44] Both saxagliptin and BMS-510849 are also highly selective for inhibition of DPP-4 compared with a large panel of other proteases tested (>4000-fold)."